Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02588586 · ClinicalTrials.gov registry record · Phase 2

A Study of the Safety and Antiretroviral Activity of 3BNC117

A Phase 2 study of HIV-1-infection, sponsored by Rockefeller University.

Completed
Registry status
Phase 2
Development phase
17
Enrollment target
2
Study locations

NCT02588586 is a Phase 2 study of HIV-1-infection that has completed, run by Rockefeller University. The registered enrollment target is 17 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02588586, a Phase 2 study of HIV-1-infection, has completed, sponsored by Rockefeller University.

COMPLETED
Registry status
Phase 2
Development phase
17 participants
Enrollment target
2
Study locations

Study Summary

This study evaluates the effects of four infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART, and its safety during a brief analytical interruption of antiretroviral therapy.

Conditions Studied

HIV-1-infection

Interventions

  • DRUG 3BNC117
  • OTHER Antiretroviral Treatment Interruption

Study Locations (2)

New York

  • The Rockefeller University - New York
  • Weill Cornel Medical Center - New York

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2015-10
Est. Completion 2018-04
Phase Phase 2

Sponsor

Rockefeller University

117 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02588586

The ClinicalTrials.gov registry entry for NCT02588586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (95% lower). The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 2 interventions - of which 3BNC117 is the first listed.

NCT02588586 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02588586 about?

NCT02588586 is a clinical study titled "A Study of the Safety and Antiretroviral Activity of 3BNC117". This study evaluates the effects of four infusions of 3BNC117 in preventing or delaying rebound of viral load during a brief treatment interruption of standard ART, and its safety during a brief analytical interruption of antiretroviral therapy.

What is the current status of trial NCT02588586?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2015-10. Estimated completion is 2018-04.

What conditions does trial NCT02588586 study?

This clinical trial studies the following conditions: HIV-1-infection.

What interventions are being tested in trial NCT02588586?

The interventions under investigation include: 3BNC117 (DRUG), Antiretroviral Treatment Interruption (OTHER).

Who is sponsoring clinical trial NCT02588586?

This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02588586 being conducted?

This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV-1-infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV-1-infection

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.